SCHEMBL14937664

SCHEMBL14937664

Cn1ncc(C#Cc2ccc(S(N)(=O)=O)cc2)c1-c1cnn(-c2ccc(C(F)(F)F)cc2)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 11/20 0.46
NTRK1 P04629 1/20 0.42
FLT3 P36888 1/20 0.42
CA12 O43570 2/20 0.42
CA2 P00918 2/20 0.42
CA9 Q16790 2/20 0.42
KIF11 P52732 1/20 0.40
CYP2C9 P11712 1/20 0.39
PDPK1 O15530 1/20 0.39
MELK Q14680 1/20 0.38
PTGS1 P23219 4/20 0.37
CA1 P00915 1/20 0.36
CA3 P07451 1/20 0.36
CA4 P22748 1/20 0.36
CA6 P23280 1/20 0.36
CA5A P35218 1/20 0.36
CA7 P43166 1/20 0.36
CA13 Q8N1Q1 1/20 0.36
CA14 Q9ULX7 1/20 0.36
CA5B Q9Y2D0 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14938215 0.89 CA1 (0.43) PTGS2CA12CA2CA9MELK
SCHEMBL14937992 0.89 NTRK1 (0.46) PTGS2NTRK1FLT3CA12CA2
SCHEMBL14937935 0.88 KIF11 (0.50) PTGS2CA12CA2CA9KIF11
SCHEMBL14937945 0.79 PTGS2 (0.42) PTGS2CA12CA2CA9KIF11
SCHEMBL14938035 0.79 MAOA (0.47) PTGS2CA2CA9KIF11PTGS1
SCHEMBL14938001 0.79 PTGS2 (0.41) PTGS2CA12CA2CA9KIF11
SCHEMBL14938076 0.79 PTGS2 (0.44) PTGS2
SCHEMBL14938283 0.79 CA2 (0.46) PTGS2NTRK1FLT3CA12CA2
SCHEMBL14938143 0.78 PTGS2 (0.46) PTGS2CA12CA2CA9KIF11
SCHEMBL14938153 0.78 CA9 (0.47) CA12CA2CA9KIF11CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8642626-B2 Ethinyl-pyrazole derivative TAISHO PHARMACEUTICAL CO., LTD. (JP) 2014-02-04 US disclosed
US-8642626-B2 Ethinyl-pyrazole derivative TAISHO PHARMACEUTICAL CO., LTD. (JP) 2014-02-04 US disclosed
US-8642626-B2 Ethinyl-pyrazole derivative TAISHO PHARMACEUTICAL CO., LTD. (JP) 2014-02-04 US disclosed
EP-2599775-A1 ETHINYL-PYRAZOLE DERIVATIVE Taisho Pharmaceutical Co., Ltd. (JP) 2013-06-05 EP disclosed
US-20130123500-A1 ETHINYL-PYRAZOLE DERIVATIVE TAISHO PHARMACEUTICAL CO., LTD (JP) 2013-05-16 US disclosed
US-20130123500-A1 ETHINYL-PYRAZOLE DERIVATIVE TAISHO PHARMACEUTICAL CO., LTD (JP) 2013-05-16 US disclosed
US-20130123500-A1 ETHINYL-PYRAZOLE DERIVATIVE TAISHO PHARMACEUTICAL CO., LTD (JP) 2013-05-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130123500-A1 ETHINYL-PYRAZOLE DERIVATIVE GABRE, GRIN3A, GRIK5 PTGS2 1318/4885NTRK1 2216/4885FLT3 2592/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.